"We are incredibly excited about joining forces with The Oncology Institute," said Selin Kurnaz, Ph.D., CEO of Massive Bio. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients." By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.Ĭristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, "This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network. NEW YORK-( BUSINESS WIRE)- Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care.
0 kommentar(er)
